Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinitech LaboratoryBOM:544220 -7.50%38 Pretax Margin % is 5.56% as of Mar. 2026, which is 41% below its 10-year median of 9.45. GuruFocus rates BOM:544220 with a GF Score™ of 38/100. The stock has 6 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Clinitech Laboratory ranks better than 63.86% on this metric.
The historical rank and industry rank for Clinitech Laboratory's Pretax Margin % or its related term are showing as below:
BOM:544220'
s Pretax Margin % Range Over the Past 10 Years
Min: 6.28 Med: 9.45 Max: 13.61
Current: 6.28
BOM:544220's Pretax Margin % is ranked better than 63.86% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.805
vs BOM:544220: 6.28
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Clinitech Laboratory Pretax Margin % Related Terms
Clinitech Laboratory Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Clinitech Laboratory's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544220 vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Clinitech Laboratory's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinitech Laboratory Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinitech Laboratory's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Clinitech Laboratory's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinitech Laboratory (BOM:544220) has a Pretax Margin % of 5.56% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Clinitech Laboratory and its competitors. This is 41% below median its historical median of 9.45. Over the past decade, Clinitech Laboratory's Pretax Margin % has ranged from 6.28 to 13.61. According to the industry distribution chart, Clinitech Laboratory ranks #73 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 36.1%.
Is Clinitech Laboratory's Pretax Margin % too high?
Clinitech Laboratory's current Pretax Margin % of 5.56% is 41% below median its 10-year median of 9.45. Over the past 10 years, this metric has ranged from a low of 6.28 to a high of 13.61. Based on the distribution chart, Clinitech Laboratory ranks #73 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Clinitech Laboratory has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Clinitech Laboratory's Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinitech Laboratory ranks #73 out of 202 companies for Pretax Margin %. This puts Clinitech Laboratory in the upper half of its industry. Historically, Clinitech Laboratory's own Pretax Margin % has ranged from 6.28 to 13.61 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Clinitech Laboratory and its competitors. Clinitech Laboratory's current Pretax Margin % is 5.56%, which is 41% below median its own 10-year median of 9.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinitech Laboratory stock overvalued right now?
Clinitech Laboratory (BOM:544220) has a current Pretax Margin % of 5.56%. The current Pretax Margin % is 5.56%, which is 41% below median its 10-year median of 9.45. Clinitech Laboratory's overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Clinitech Laboratory (BOM:544220), the current Pretax Margin % is 5.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clinitech Laboratory Ltd is an Indian diagnostic and healthcare services provider company. It operates a network of diagnostic centers in Thane and Navi Mumbai and offers various medical tests across multiple specialties, including biochemistry, immunology, hematology, molecular biology, serology, microbiology, and histopathology. It serves individual patients as well as corporate clients, aiming to provide affordable and comprehensive diagnostic solutions.
38GF Score
Get the complete analysis for BOM:544220
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544220 has been successfully added to your 
